- Research Article
- 10.1093/ecco-jcc/jjaf231.073
DOP036 Real-world corticosteroid use in patients with Ulcerative Colitis receiving filgotinib up to week 24: An interim analysis from the prospective, observational GALOCEAN study
- Jan 01, 2026
- Journal of Crohn’s and Colitis
- S W Schreiber + 13 more +13
Abstract Background Filgotinib (FIL) is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for the treatment of adults with moderately to severely active Ulcerative Colitis (UC)1. In the phase 2b/3 SELECTION trial, FIL demonstrated corticosteroid (CS)-sparing effects in patients with UC.2,3 Here, we aimed to characterise real-world systemic CS use in patients with UC receiving FIL. Methods GALOCEAN (NCT05817942) is an ongoing, European, multicentre, prospective, observational study of adults with UC receiving FIL in routine care; this interim analysis reports data up to week (W) 24. Baseline (BL) characteristics, systemic CS use during FIL treatment, and effectiveness outcomes through W24 were analysed for patients receiving FIL with BL CS use (FIL+CS) or without BL CS use (FIL–CS). Effectiveness outcomes assessed at BL, W10 and W24 were the partial Mayo Clinic Score (pMCS), two-item patient-reported outcome (PRO2) score and the proportion of patients in pMCS or PRO2 remission. Results As of 15 January 2025, 353 enrolled patients had BL data; 253 and 164 patients had data at W10 and W24, respectively. At BL, CS use was low; 93 out of 353 patients (26.3%) were in the FIL+CS group and 260 out of 353 patients (73.7%) were in the FIL–CS group. BL characteristics are summarized in Table I. Compared with FIL–CS, the FIL+CS group included a higher proportion of men (66.7% vs 45.8%) and more prior 5-aminosalicylate use (80.6% vs 69.2%), but fewer patients with prior exposure to advanced therapies (54.8% vs 79.6%). In the FIL+CS group, the proportion of patients using CS decreased from BL to 59.4% (41/69 patients) and 46.5% (20/43 patients) at W10 and at W24, respectively. A small number of patients in the FIL–CS group were using CS at W10 (4.4% [8/180] patients) and W24 (3.4% [3/88] patients) (Figure I). Improvements from BL in pMCS and PRO2 score were observed at W10 and W24 in both the FIL+CS and FIL–CS groups (Figure I). In addition, the proportion of patients in pMCS remission increased from 37.5% (24/64 patients) to 45.2% (19/42 patients) in the FIL+CS group and 43.0% (74/172 patients) to 57.6% (53/92 patients) in the FIL–CS group at W10 and W24, respectively. A similar pattern was observed for PRO2 remission (Figure I). Conclusion This real-world analysis showed that in the small number of patients with UC using CS at BL, over half were no longer using CS by W24 after initiating FIL. Patients achieved symptomatic remission and showed improvements in clinical symptoms over time following FIL treatment, irrespective of CS use at BL. These findings support that FIL treatment offers an opportunity for patients to reduce or minimise their CS use, consistent with results from the SELECTION trial.3
Read more